Caribou Biosciences, Inc.
CRBU
$0.7331
-$0.046-5.90%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 9.99M | 11.48M | 33.11M | 33.40M | 34.48M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.99M | 11.48M | 33.11M | 33.40M | 34.48M |
| Cost of Revenue | 128.95M | 130.37M | 129.13M | 120.15M | 112.08M |
| Gross Profit | -118.96M | -118.89M | -96.02M | -86.75M | -77.60M |
| SG&A Expenses | 42.56M | 41.79M | 45.56M | 44.20M | 38.46M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 171.51M | 172.16M | 174.69M | 164.35M | 150.54M |
| Operating Income | -161.52M | -160.68M | -141.58M | -130.95M | -116.06M |
| Income Before Tax | -149.11M | -147.93M | -123.25M | -115.07M | -101.88M |
| Income Tax Expenses | -9.00K | 193.00K | 193.00K | 193.00K | 193.00K |
| Earnings from Continuing Operations | -149.11 | -148.12 | -123.44 | -115.26 | -102.07 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -149.11M | -148.12M | -123.44M | -115.26M | -102.07M |
| EBIT | -161.52M | -160.68M | -141.58M | -130.95M | -116.06M |
| EBITDA | -157.59M | -157.20M | -137.69M | -127.30M | -112.53M |
| EPS Basic | -1.65 | -1.65 | -1.39 | -1.45 | -1.45 |
| Normalized Basic EPS | -1.00 | -1.00 | -0.87 | -0.91 | -0.90 |
| EPS Diluted | -1.65 | -1.65 | -1.39 | -1.45 | -1.45 |
| Normalized Diluted EPS | -1.00 | -1.00 | -0.87 | -0.91 | -0.90 |
| Average Basic Shares Outstanding | 361.26M | 358.53M | 351.86M | 322.94M | 294.82M |
| Average Diluted Shares Outstanding | 361.26M | 358.53M | 351.86M | 322.94M | 294.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |